INNOVATE Corp. (VATE)
| Market Cap | 226.32M +181.1% |
| Revenue (ttm) | 1.34B +25.4% |
| Net Income | -56.40M |
| EPS | -4.25 |
| Shares Out | 13.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 60,552 |
| Open | 16.68 |
| Previous Close | 16.72 |
| Day's Range | 16.27 - 17.55 |
| 52-Week Range | 3.75 - 19.59 |
| Beta | 2.34 |
| Analysts | Strong Buy |
| Price Target | 50.00 (+201.39%) |
| Earnings Date | Aug 4, 2026 |
About VATE
INNOVATE Corp., through its subsidiaries, operates in infrastructure, life sciences, and spectrum areas in the United States. The company operates through the Infrastructure, Life Sciences, and Spectrum segments. The Infrastructure segment provides industrial construction, structural steel, and facility maintenance services, such as fabrication and erection of structural steel and heavy steel plate services, and large-diameter water pipes and water storage tanks; fabrication of trusses and girders; 3-D building information modeling and detailin... [Read more]
Financial Performance
In 2025, INNOVATE's revenue was $1.25 billion, an increase of 12.55% compared to the previous year's $1.11 billion. Losses were -$64.00 million, 78.8% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for VATE stock is "Strong Buy" and the 12-month stock price target is $50.0.
News
INNOVATE Transcript: AGM 2026
Directors and executive officers were introduced, and all four shareholder proposals—including director elections, executive compensation, equity plan amendment, and auditor ratification—were approved. No questions were submitted during the Q&A session.
INNOVATE Announces Successful Closing of Broadcasting Refinancing and Agrees to Partial Sale of Broadcasting
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that HC2 Broadcasting Holdings Inc. (“Broadcasting”) closed on a refinancing trans...
INNOVATE Earnings Call Transcript: Q1 2026
Q1 2026 saw 33% revenue growth to $364.8M and improved adjusted EBITDA, driven by infrastructure gains, while Life Sciences and Spectrum faced revenue declines. Net loss narrowed, cash increased, and backlog remains strong, supporting a positive outlook.
INNOVATE Slides: Q1 2026
INNOVATE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.
INNOVATE Earnings release: Q1 2026
INNOVATE released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
INNOVATE Quarterly report: Q1 2026
INNOVATE has published its Q1 2026 quarterly earnings report on May 14, 2026.
INNOVATE Corp. Announces First Quarter 2026 Results
- Infrastructure: Strong first quarter results with revenue of $357.9 million - Life Sciences: MediBeacon receives the CE mark for the Transdermal GFR Monitor and Reusable Sensor - Spectrum: More tha...
INNOVATE Proxy statement: Proxy filing
INNOVATE filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
INNOVATE Proxy statement: Proxy filing
INNOVATE filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
INNOVATE Corp. to Report First Quarter 2026 Results on May 14th
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the first quarter 2026 on Thursday...
INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully integrated s...
MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in...
INNOVATE Earnings Call Transcript: Q4 2025
Fourth quarter revenue surged 61.7% year-over-year, driven by infrastructure, while net loss narrowed. Life sciences and spectrum segments faced headwinds, but regulatory wins and backlog growth position the company for 2026 expansion.
INNOVATE Annual report: Q4 2025
INNOVATE has published its Q4 2025 annual report on March 26, 2026.
INNOVATE Earnings release: Q4 2025
INNOVATE released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
INNOVATE Slides: Q4 2025
INNOVATE has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 26, 2026.
INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results
- Infrastructure: NYC and Western markets continue to demonstrate positive project momentum - - Life Sciences: R2 Secures 600‑System Commitment in China - - Spectrum: Recent network launches set to de...
INNOVATE Corp. to Report Fourth Quarter and Full Year 2025 Results on March 26th
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the fourth quarter and full year 2...
Transdermal GFR Article Recognized as One of Five 2025 Editors' Choice Articles by Journal of the American Society of Nephrology (JASN)
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in ...
INNOVATE Corp.’s DBM Global to pay $1.30 per share dividend
INNOVATE Corp. (VATE) announced that DBM Global, an operating subsidiary of INNOVATE, will pay a cash dividend of approximately $5M, or $1.30 per share, on February 24, 2026 to DBMG’s…
INNOVATE announces MediBeacon received approval for TGFRTM System
INNOVATE announced that MediBeacon, in which INNOVATE owns a 44.7% equity interest, has received approval from the U.S. Food and Drug Administration, FDA, for the next generation MediBeacon TGFRTM Sys...
MediBeacon® Next Generation TGFR™ System Receives FDA Approval
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in ...
INNOVATE Earnings Call Transcript: Q3 2025
Q3 2025 revenue rose 43% year-over-year to $347.1M, led by infrastructure and life sciences growth, while net loss narrowed. DBM Global's backlog and R2's international sales surged, and MediBeacon secured key regulatory approval in China.
INNOVATE Earnings release: Q3 2025
INNOVATE released its Q3 2025 earnings on November 12, 2025, summarizing the period's financial results.
INNOVATE Quarterly report: Q3 2025
INNOVATE has published its Q3 2025 quarterly earnings report on November 12, 2025.